Besponsa beats CAR-T frontrunner to US market – The Pharma Letter (registration)
|
Besponsa beats CAR–T frontrunner to US market
The Pharma Letter (registration) In timely fashion, US pharma giant Pfizer (NYSE: PFE) has received US Food and Drug Administration (FDA) approval for Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia … |
